

producing an antibody against a polypeptide of SEQ ID NO: 4;

Group XI: Claims 51-54 (in part), directed to a method of treatment of a subject with a polypeptide of SEQ ID NO: 2;

Group XII: Claims 51-54 (in part), directed to a method of treatment of a subject with a polypeptide of SEQ ID NO: 4;

Group XIII: Claims 55, directed to a method of diagnosing the level of huE3 α ;

Group XIV: Claims 56 and 57 (in part), directed to a device comprising a polypeptide of SEQ ID NO: 2;

Group XV: Claims 56 and 57 (in part), directed to a device comprising a polypeptide of SEQ ID NO: 4;

Group XVI: Claim 65 (in part), directed to a method of treatment of an animal with a DNA of SEQ ID NO: 1;

Group XVII: Claim 65 (in part), directed to a method of treatment of an animal with a DNA of SEQ ID NO: 3; and

Group XVIII: Claim 66, directed to a transgenic non-human animal.

III. ELECTION

In view of the restriction requirement, the applicants hereby elect for further prosecution on the merits the invention of Group I (claims 1-8, 10, 11, 46-48 and 59-64), without traverse.

IV. REMARKS


This response is timely filed as it is accompanied by a petition for a one month extension of time. The foregoing amendments to the claims were necessitated by the restriction requirement dated December 31, 2001. Specifically, the applicants have amended claims 1-3 and 59 to be directed to the DNA sequence of the examiner's Group I. As a convenience to the examiner, the applicants have set forth (1) a marked

up version of the amended claims in **Appendix A**, and (2) the claims as they should appear after entry of the foregoing amendment in **Appendix B**.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By



Thomas A. Cawley, Jr., Ph.D.
Registration No. 40,944
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

February 6, 2002